Topotecan (NSC609699) HCl

製品コード:S1231 別名:Nogitecan HCl, SKFS 104864A

For research use only.

Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.

Topotecan (NSC609699) HCl化学構造

CAS No. 119413-54-6

サイズ 価格(税別)
10mM (1mL in DMSO) JPY 40100
JPY 31800
JPY 55100

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(42)

製品安全説明書

Topoisomerase阻害剤の選択性比較

相関Topoisomerase製品

生物活性

製品説明 Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.
特性 Topotecan is a water-soluble derivative of camptothecin.
ターゲット
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
体外試験

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells MVHDfZRwfG:6aXRCpIF{e2G7 NInrNGg4OiCq NFvJRZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJIlkPTB;MTDuUS=> NUjjUZlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzO|EyQDNpPkKwN|cyOTh|PD;hQi=>
human Bel7402 cells MXLDfZRwfG:6aXRCpIF{e2G7 M2XYXlk3KGh? M3\mRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJmdDd2MEKgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjJibl2= NHjDRXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG2OVE1PCd-MUWxOlUyPDR:L3G+
human HCT8 cells MlfSR5l1d3SxeHnjxsBie3OjeR?= NIfublQ6PiCq M3PxdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlUhdk1? MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human MCF7 cells M4nOPGN6fG:2b4jpZ:Kh[XO|YYm= MX:5OkBp M{DyZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlghdk1? NGP6PIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG2OVE1PCd-MUWxOlUyPDR:L3G+
human A549 cells NITEbGhEgXSxdH;4bYPDqGG|c3H5 NI[3WIc6PiCq MnPXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOuNkBvVQ>? M4X2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MU[1NVQ1Lz5zNUG2OVE1PDxxYU6=
human colon carcinoma SW620 cell NHP6XWREgXSxdH;4bYPDqGG|c3H5 M1vFfmN6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIHj1cYFvKGOxbH;uJINiemOrbn;tZUBUXzZ{MDDj[YxtKGyrbnWsJGlEPTB;Mz6yJI5O Mne4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2MEi3NFcoRjF{NEC4O|A4RC:jPh?=
human MESSA cells NGLTOoNEgXSxdH;4bYPDqGG|c3H5 MUG3NkBp NFW0eJNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVOVQTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9OEBvVQ>? NITGeFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0NVY4PCd-MkGzOFE3PzR:L3G+
human BGC823 cells M{Tm[WN6fG:2b4jpZ:Kh[XO|YYm= MlO4PVYhcA>? MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlMhdk1? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTF4NUG0OEc,OTVzNkWxOFQ9N2F-
human Ketr3 cells M2Tab2N6fG:2b4jpZ:Kh[XO|YYm= M33mVFk3KGh? M{\1ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmfHJ|IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE46KG6P NIHUUGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG2OVE1PCd-MUWxOlUyPDR:L3G+
LOX cells NF;oWZREgXSxdH;4bYPDqGG|c3H5 NEDB[WhEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iTF;YJINmdGy|IDjt[Yxidm:vYTmgc4YhcHWvYX6geJVud3JiY3XscEBtcW6nczDifUB2e2mwZzDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzh3M{OzNUc,Pzh3M{OzNVww[T5?
human A549 cells NHLGT3ZHfW6ldHnvckBie3OjeR?= NXPrTlh4PCCq NETrdnFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IESgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13IH7N MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJyN{e0PEc,OTh{MEe3OFg9N2F-
human H69 cells NGr6bo9EgXSxdH;4bYPDqGG|c3H5 MVu3NkBp MnHDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFY6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD14IH7N MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human A2780 cells MWDDfZRwfG:6aXRCpIF{e2G7 M3O4blczKGh? Mn;OR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMhd3[ncnX4dJJme3OrbnegZYxxcGF3YnX0ZVMhcW62ZXfybY4h[XO|ZYPz[YQh[XNiY3XscEB{fXK4aY\hcEBi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPU[gcm0> NYjjSWJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OVkzPDZpPkKyPVU6OjR4PD;hQi=>
human LNCAP cells NHjhdo5EgXSxdH;4bYPDqGG|c3H5 NHP2WJE4OiCq MlrtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUmgcm0> M3H0T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human HOP62 cells Mmr1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn3KS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTG9RPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human MCF7 cells MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHhS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MEmyO|koRjJ3OUC5Nlc6RC:jPh?=
human UACC62 cells NGjaNphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFfYbZlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWSUOFNkKgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human DU145 cells MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3pS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P NWfnc|ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NFkzPzlpPkK1PVA6Ojd7PD;hQi=>
LoVo cell line NGDCRVFEgXSxdH;4bYPDqGG|c3H5 NGjkNVBEgXSxdH;4bYMheG:2ZX70bYF1cW:wIH;mJHRweG:2ZXPhckApXFBrIHL5JJRp\SClb33wc5Vv\CCrbjCobJVu[W5iY3;sc5Jm[3SjbDDjZY5k\XJiTH;Wc{Bk\WyuIHzpcoUtKEmFNUC9NVEvPiCwTR?= M2W5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEC4O|A4Lz5zMkSwPFcxPzxxYU6=
human lymphoblast tumor cell line RPM18402 NWX4WJU2S3m2b4TvfIlkyqCjc4PhfS=> MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOOTh2MEKsJGlEPTB;MUKgcm0> MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ|OUK3OFUoRjF{M{myO|Q2RC:jPh?=
human HL60 cells MorSSpVv[3Srb36gZZN{[Xl? NULyeolVSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxRTF{IH7N MkDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
human A375 cells MUnDfZRwfG:6aXRCpIF{e2G7 M3niN|czKGh? MlqwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MUOgcm0> NXy5OpJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOFE3PzRpPkKxN|QyPjd2PD;hQi=>
COR-L23/P cell M{e0WGN6fG:2b4jpZ:Kh[XO|YYm= MWLDfZRwfG:6aXPpeJkhdWWjc4Xy[YQhfXOrbnegeIhmKEORUj3MNlMheGG{ZX70ZYwhMEORUj3MNlMwWCliaIXtZY4hdm:wIIPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nLDDJR|UxRTF|LkKgcm0> MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6ME[3NlQoRjFzOEC2O|I1RC:jPh?=
human NCI-H460 cells NEj4bVZRem:uaX\ldoF1cW:wIHHzd4F6 M4rX[VczKGh? MmO5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6M{O2PUc,OjF5OEOzOlk9N2F-
human MOLT4 cells NF:zeWREgXSxdH;4bYPDqGG|c3H5 MkTtO|IhcA>? NVLxeHByS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVU:OVESgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQSCwTR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEeyOUc,OjR7MEC3NlU9N2F-
human LoVo cells MmfuR5l1d3SxeHnjxsBie3OjeR?= M1LIPVczKGh? MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkCgcm0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN5MUG4N{c,OjB|N{GxPFM9N2F-
RPM18402 tumor cell line NEDwTpZRem:uaX\ldoF1cW:wIHHzd4F6 NIPvcIVEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;uJIlvKFKSTUG4OFAzKHS3bX;yJINmdGxibHnu[UwhUUN3ME2yNEBvVQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTR6MkmyPUc,OTV2OEK5Nlk9N2F-
human SN12C cells NUfNe49GT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTUlEzSyClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEeLNUC9NlAhdk1? M4rHeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUC5Nlc6Lz5{NUmwPVI4QTxxYU6=
human RPMI8226 cells MVvDfZRwfG:6aXRCpIF{e2G7 NH7Tb4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWE2LOEKyOkBk\WyuczDifUBOXFRibXX0bI9lNCCLQ{WwQVIyKG6P NYTYdFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNVI6QTZpPkG5NFEzQTl4PD;hQi=>
HT-29 cells MknIR5l1d3SxeHnjxsBie3OjeR?= NHTHWFVEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iSGStNlkh[2WubIOoZ49td25rIH;mJIh2dWGwIIT1cY9zKGOnbHygcIlv\XNiYomgeZNqdmdiTWTUJIF{e2G7LDDJR|UxRTJ3IH7N M4DhTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd6NUOzN|EoRjd6NUOzN|E9N2F-
SK-BR-3 cells MVXDfZRwfG:6aXRCpIF{e2G7 MmjSTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsJIxqdmViKGPLMWJTNTNrLDDJR|UxRTJ4IH7N MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN|NEW2PUc,OTF|M{S1Olk9N2F-
HeLa cells Ml3US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGHmbJdIem:5dHigbY5pcWKrdHnvckBw\iCKZVzhJINmdGy|IHHmeIVzKDRiZHH5d{whT0l3ME2zNEBvVQ>? NETEfFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxPFU5Oid-MUe0NVg2QDJ:L3G+
UACC 62 cells MVLDfZRwfG:6aXRCpIF{e2G7 MknZWIV{fGWmIHnuJJZqfHKxIH\vdkBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1fW2xcjDj[YxtKGyrbnWgWWFESyB4MjCocYVt[W6xbXGpMEBIUTVyPUOwJI5O M1PwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{G0OVAzLz5zMEexOFUxOjxxYU6=
human HCT116 cells NHLDNohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPMSWNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDHTVUxRTNyIH7N MnjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MEmyO|koRjJ3OUC5Nlc6RC:jPh?=
human lung cancer cell line (H128) NH7tXnpEgXSxdH;4bYPDqGG|c3H5 NXHwVIt5UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdHWwZzDjZY5k\XJiY3XscEBtcW6nIDjINVI5MSxiSVO1NF0{OSCwTR?= NFToOmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human MES-SA/Dx5 cells MWnDfZRwfG:6aXRCpIF{e2G7 MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTN|IH7N MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human A2780 cells MXvDfZRwfG:6aXRCpIF{e2G7 MUG3NkBp MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOzJI5O MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEeyOUc,OjR7MEC3NlU9N2F-
human MDA-MB-435 cells MWTDfZRwfG:6aXRCpIF{e2G7 M3Tn[FczKGh? NHH4PZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OD1|NDDuUS=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh4N{CxPUc,OjJ6NkewNVk9N2F-
human stomach cancer cell line (MKN45) M{jIUWN6fG:2b4jpZ:Kh[XO|YYm= MUjJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDzeI9u[WOqIHPhcoNmeiClZXzsJIxqdmViKF3LUlQ2MSxiSVO1NF0{QCCwTR?= NELETWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human KB3-1 cells NHrPWFdEgXSxdH;4bYPDqGG|c3H5 M1jzVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDOy1zIHPlcIx{KGGodHXyJG1VXCCjc4PhfUwhUUN3ME20NEBvVQ>? M2PrUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEK5N|M1Lz5zOEiyPVM{PDxxYU6=
mouse P388 cells NIny[nFEgXSxdH;4bYPDqGG|c3H5 MorBR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh{OUOzOEc,OTh6MkmzN|Q9N2F-
A427 human lung carcinoma NYDk[4V5WHKxbHnm[ZJifGmxbjDhd5NigQ>? M4Lw[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JI1m[XO3cnXkJIFo[Wmwc4SgRVQzPyCqdX3hckBtfW6pIHPhdoNqdm:vYTygTWM2OD12OTDuUS=> NImzb2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEe2NVEyLz57OEe2NVEyRC:jPh?=
human U251 cells M{XzbWZ2dmO2aX;uJIF{e2G7 NIrRTYk3NTJ2IHi= M4n5U2lvcGmkaYTpc44hd2ZidH;wc4l{d22ncnHz[U0yKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmILUHhcJBp[SCjY3P1cZVt[XSrb36gbY4hdnWlbHXhdkBmgHS{YXP0JIFnfGW{IE[geI8hOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXNuIFXDOVA:PTRibl2= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyNU[xNkc,OjJ|MEW2NVI9N2F-
human colon cancer cell line (WiDr) MlnuR5l1d3SxeHnjxsBie3OjeR?= M1HiXmlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsJIxqdmViKGfpSJIqNCCLQ{WwQVU3KG6P MnXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human HepG2 cells M3vNZ2N6fG:2b4jpZ:Kh[XO|YYm= NFXKO5Y1KGSjeYO= MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPU[wJI5O MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUS5NFYoRjF6NUW0PVA3RC:jPh?=
human KB cells NW\JfG9[S3m2b4TvfIlkyqCjc4PhfS=> M{P3flczKGh? MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= NE\wcIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPFQ2Pid-MkWwNFg1PTZ:L3G+
human HCT8 cells MoDUR5l1d3SxeHnjxsBie3OjeR?= NVjMOZpiOyCmYYnz MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;N{Cgcm0> NEPVboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO5NlU1PSd-MkCzPVI2PDV:L3G+
human GBM2 cells NU\6SpFyWHKxbHnm[ZJifGmxbjDhd5NigQ>? MlP3O|IhcA>? MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlE{KM7:TR?= MmDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUW1N|IoRjJ4M{W1OVMzRC:jPh?=
SK-MEL-2 cells M37CR2N6fG:2b4jpZ:Kh[XO|YYm= NH33XWQ4OiCq MlvsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVUWOLUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVAvOTRizszN M4fPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human IGROV1 cells M3m0cWN6fG:2b4jpZ:Kh[XO|YYm= M2rWTlczKGh? NUTRdYRrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUUeUT2[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF4IN88US=> MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human U87 cells M{GyXXBzd2yrZnXyZZRqd25iYYPzZZk> M4ToNlQ5KGh? M{LrbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOkDPxE1? NGC0bnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiyOlgyQCd-MkS4NlY5OTh:L3G+
human HT1080 cells NGPXW4xRem:uaX\ldoF1cW:wIHHzd4F6 MVe0PEBp MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMUC4NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwQVAvOThizszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyOEixOUc,OjZ2MEi4NVU9N2F-
human Hep3B cells NFzOOpdRem:uaX\ldoF1cW:wIHHzd4F6 NHLaTIE4OiCq MnLuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYCzRkBk\WyuczDh[pRmeiB5MjDodpMh[nliWGTUJIF{e2G7LDDHTVUxRTBwMkKg{txO MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd7Nkm1Okc,OTl5OU[5OVY9N2F-
human GBM3 cells NGK3RmRRem:uaX\ldoF1cW:wIHHzd4F6 Mk\VO|IhcA>? MkXLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE4{QCEQvF2= MnX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUW1N|IoRjJ4M{W1OVMzRC:jPh?=
human KBVIN cells NYnKcYZqS3m2b4TvfIlkyqCjc4PhfS=> M1LB[lczKGh? NH64VHNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSl[LTjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2= Mm[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{i3OlkoRjJ3NEO4O|Y6RC:jPh?=
human GBM1 cells NWXobXRFWHKxbHnm[ZJifGmxbjDhd5NigQ>? M17rTFczKGh? Mn62RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2xJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE41PiEQvF2= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3NUWzNkc,OjZ|NUW1N|I9N2F-
human U937 cells M2DsfGN6fG:2b4jpZ:Kh[XO|YYm= NIHhe2g1QCCq MlnmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{BmgHC{ZYPzbY5oKHB3MzDteZRidnRiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSExvJygTWM2OD1zLkGg{txO M2jRW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G1N|E6Lz5zOUexOVMyQTxxYU6=
Caco2 NXjtPFlmS3m2b4TvfIlkcXS7IHHzd4F6 NWXVNoV5OjRiaILz NHnmc3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[WOxMjDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF7zszNMi=> MmHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
Jurkat NHrGUoxEgXSxdH;4bYNqfHliYYPzZZk> MlG5NlQhcHK| NYPUPYFvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUnW{a3H0JINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zMkhOwG0v M3XrXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
A375 Ml;DR5l1d3SxeHnjbZR6KGG|c3H5 NUn1[IpSOjRiaILz NGXZSHhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOzd3IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4yPjMQvF2u M{\xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
HeLa MUjDfZRwfG:6aXPpeJkh[XO|YYm= M{X2SlI1KGi{cx?= NUXLXWlGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOzkQvF2u NFTSNJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
MDA-MB-231 M1\kbWN6fG:2b4jpZ4l1gSCjc4PhfS=> MkjxNlQhcHK| M3frTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkS3N:69VS5? NITnUFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
NCI-H460 MoXsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFjtT2syKGi{ MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IIPoc5J1KHSncn2g[Zhxd3O3cnWg[o9zKDFiaIKgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGmwIHTyeYcu\nKnZTDt[YRqfW1uIFnDOVA:OC54Md88UU4> NWGwN2cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N|A4OjBpPkG5OVMxPzJyPD;hQi=>
HCT8 MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHHSXoM1QCCqcoO= NV\4OWJ4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyPUGuPFc2|ryPLh?= NX3UOnljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFE{QTVpPkK1OFgyOzl3PD;hQi=>
KB M1\SfGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MV60PEBpenN? M3fPe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEOFS{igZZN{[XluIFnDOVA:Oi5{OENOwG0v NHjZems9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4NVM6PSd-MkW0PFE{QTV:L3G+
SGC7901 NFrY[lJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUW0PEBpenN? NGnHbJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPHR|c6ODFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JGNEUzhiYYPzZZktKEmFNUC9Nk4zQTMQvF2u MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MUO5OUc,OjV2OEGzPVU9N2F-
HepG2 NXfyfXZESW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{TESlQ5KGi{cx?= NUfLeFFJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgR2NMQCCjc4PhfUwhUUN3ME20MlIxQM7:TT6= MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEGzPVUoRjJ3NEixN|k2RC:jPh?=
MDA-MB-231 MVHBdI9xfG:|aYOgZZN{[Xl? NVexNmk3UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJJA2OyCyaH;zdIhwenmuYYTpc44h[XRiU3XyNVUh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? NETJcXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
HeLa MYTBdI9xfG:|aYOgZZN{[Xl? M13TUlAvQCC2bzCxMlYhfU1? MUmyOEBpenN? M13s[2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFTORUB{gW62aHXzbZMh[XRiMD64JJRwKDFwNjD1UUBi\nSncjCyOEBpenNiYomgRpJlXSC|dHHpcolv\y2kYYPl[EBGVEmVQR?= M{TZS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
MDA-MB-231 MX\BdI9xfG:|aYOgZZN{[Xl? NV;kdYlIOC56IITvJFEvPiC3TR?= MXmyOEBpenN? NX3qXHBmUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRF7BJJN6dnSqZYPpd{BifCByLkigeI8hOS54IIXNJIFnfGW{IEK0JIhzeyCkeTDCdoRWKHO2YXnubY5oNWKjc3XkJGVNUVOD M2jhR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
A375 NEfmRmNCeG:ydH;zbZMh[XO|YYm= MoDxNE45KHSxIEGuOkB2VQ>? NWHBSY1yOjRiaILz MXfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEF|N{WgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCGTlGgd5lvfGinc3nzJIF1KDBwODD0c{AyNjZidV2gZYZ1\XJiMkSgbJJ{KGK7IFLy[HUhe3SjaX7pcocu[mG|ZXSgSWxKW0F? NHHESpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
Caco2 NG\JT|FCeG:ydH;zbZMh[XO|YYm= MVmwMlghfG9iMT62JJVO NGXseXczPCCqcoO= NGSxV|JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFPhZ48zKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHO7boTo[ZNqeyCjdDCwMlghfG9iMT62JJVOKGGodHXyJFI1KGi{czDifUBDemSXIIP0ZYlvcW6pLXLhd4VlKEWOSWPB M1nMPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
A375 NULCWZhZSXCxcITvd4l{KGG|c3H5 MVTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEF|N{WgZ4VtdHNiYYPz[ZN{\WRiYYOgdFU{KHCqb4PwbI9zgWyjdHnvckBifCCVZYKxOUBjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
TC32 MkDldWhVWyCjc4PhfS=> NWGzU2lqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MYHxTHRUKGG|c3H5 MnvFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NUD3O4JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NInvTFdyUFSVIHHzd4F6 MlnudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MYDxTHRUKGG|c3H5 M3HCW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NWnE[plmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NYTJPWVseUiWUzDhd5NigQ>? MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 MYPxTHRUKGG|c3H5 Ml7KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NX;0SGRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MojjdWhVWyCjc4PhfS=> NEjVVmdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> NGjJUG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MoLOdWhVWyCjc4PhfS=> MnTKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= NF\4eo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M3H4e5FJXFNiYYPzZZk> MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NFPsd4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M4i3SpFJXFNiYYPzZZk> NIfwUYRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MlywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NWrsNmJweUiWUzDhd5NigQ>? MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? M2PIOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NYfnUXFLeUiWUzDhd5NigQ>? NVjnO3ZEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NFfr[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NX;JZnhNeUiWUzDhd5NigQ>? MnPrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MonNdWhVWyCjc4PhfS=> M2ruWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NVLxbW5xeUiWUzDhd5NigQ>? M2fBOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NFq4[pY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M4W1RZFJXFNiYYPzZZk> NX\JN4YyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 M2jrdZFJXFNiYYPzZZk> MoDqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MV;xTHRUKGG|c3H5 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM> M2rt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NXW3fVI2eUiWUzDhd5NigQ>? NV21dFBseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? M4\sV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NYDt[lM4eUiWUzDhd5NigQ>? M1jQc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 M3zUcZFJXFNiYYPzZZk> NWXoN4R6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M4DBPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 Mn\PdWhVWyCjc4PhfS=> NX;PXXpmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NGHFNIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY NXPsO2hneUiWUzDhd5NigQ>? NHz0PXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{ MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MVjxTHRUKGG|c3H5 MmjpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NGrBdoxyUFSVIHHzd4F6 NFe1[mRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy| MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M4XxUZFJXFNiYYPzZZk> NXHxclZweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 M3vDbZFJXFNiYYPzZZk> M1H5OJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> M1P6W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MmPudWhVWyCjc4PhfS=> NVXCenAzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
U-2 OS NWfGfI9DeUiWUzDhd5NigQ>? NW\CWmxneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| NFzQe5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MY\xTHRUKGG|c3H5 NFPWU2FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ M4LIOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD MWLxTHRUKGG|c3H5 NYLrUnZreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> MmXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 MX;xTHRUKGG|c3H5 NELESZlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{ MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 NEjldGpyUFSVIHHzd4F6 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz NH3JN5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MmXudWhVWyCjc4PhfS=> M4m5WZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>? NVHqe25mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M3LjRZFJXFNiYYPzZZk> NV30SmU2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MXXxTHRUKGG|c3H5 MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ M2TSVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MVLxTHRUKGG|c3H5 MlrKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| NWTyVoRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NUewVYJ2eUiWUzDhd5NigQ>? NUTCXJhReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M1XpZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Daoy NYDEfllleUiWUzDhd5NigQ>? MmC1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{ MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 Mn3hdWhVWyCjc4PhfS=> M2P2c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1SgZ4F{eGG|ZTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> NEXNTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NUS1SYpqeUiWUzDhd5NigQ>? NWWyNXhreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| NGPIe4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MonVdWhVWyCjc4PhfS=> NX3xTIJJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NYr6TVBZeUiWUzDhd5NigQ>? NGO5NXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{ NH7v[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
アッセイ
Methods Test Index PMID
Western blot LC3 / p62 ; p53 / sesn2 / p-AMPK 23024792
Growth inhibition assay Cell viability 28544814
体内試験 Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

  • 細胞株:MCF-7 Luc and DU-145 Luc cells
  • 濃度: 0 μg/mL - 0.692 μg/mL
  • 反応時間:96 hours
  • 実験の流れ:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.

動物試験:

[1]

  • 動物モデル:Mice with MCF-7 Luc or DU-145 Luc cells
  • 投薬量:0.25 mg/mL
  • 投与方法:Administered via i.p.

溶解度 (25°C)

体外

体内

左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。

30 mg/mL

化学情報

分子量 457.91
化学式

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage 3年 -20°C
2年 -80°C in solvent
Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04455139 Recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals November 15 2021 Phase 2
NCT05083000 Recruiting Drug: Topotecan COVID-19 Respiratory Infection National University Hospital Singapore|Christian Medical College Vellore India August 16 2021 Phase 1
NCT04156347 Recruiting Drug: Episcleral Topotecan Retinoblastoma Targeted Therapy Technologies LLC June 16 2021 Phase 1
NCT04428879 Recruiting Drug: Topotecan Episcleral Plaque Retinoblastoma The Hospital for Sick Children June 16 2020 Phase 1
NCT03927274 Suspended Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute June 20 2019 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

回答
Topotecan HCl is generally prepared by Saline for I.P. administration.

Tags: Topotecan (NSC609699) HClを買う | Topotecan (NSC609699) HCl ic50 | Topotecan (NSC609699) HCl供給者 | Topotecan (NSC609699) HClを購入する | Topotecan (NSC609699) HCl費用 | Topotecan (NSC609699) HCl生産者 | オーダーTopotecan (NSC609699) HCl | Topotecan (NSC609699) HCl化学構造 | Topotecan (NSC609699) HCl分子量 | Topotecan (NSC609699) HCl代理店